Safety and Efficacy Study to Compare IV CXA 101/Tazobactam and Metronidazole With Meropenem in Complicated Intraabdominal Infections

• Status: Completed
• Trial end date: 2011-03-25

Summary

A Phase 2, multicenter, prospective, randomized, double-blind study of CXA-101/ tazobactam (1000/500 mg q8h) and metronidazole (500 mg q8h) IV infusion vs. meropenem IV infusion (1000 mg q8h) and a matching saline placebo (q8h) in the treatment of cIAI in adult subjects. Dose adjustments for subjects with mild renal impairment are not necessary and subjects with more severe degrees of renal failure are excluded.

• Phase: Phase 2

Details

• Lead Sponsor: Cubist Pharmaceuticals LLC
• Treatments: Ceftolozane; Cephalosporins; Meropenem; Metronidazole; Penicillanic Acid; Tazobactam; Thienamycins